Non-small cell lung cancer (NSCLC) and EGFR/ALK inhibitors affect patients with NSCLC (those with adenocarcinoma and who are not smokers) who have mutations in the EGFR genes or rearrangements in the ALK gene [261]. This evidence concerns the gene ALK and adenocarcinoma.